Cancer patients are clinically distinguished by CD8+ T-cells and type I interferon (IFN-α/β) into T-cell-inflamed (CD8 T-cell infiltration and type I interferon marker positivity) and non-T-cell-inflamed patients (lack of both features) (Spranger 2016). This evidence concerns the gene CD8A and cancer.